Cantor Fitzgerald analyst Louise Chen assigned a Buy rating to Perrigo Company plc (NYSE: PRGO) yesterday and set a price target of $107. The company’s shares closed yesterday at $78.03.
Chen noted:
“We rate PRGO 12-month price target of $107. Perrigo has been through a lot over the past two years, but we think the Street can finally refocus on fundamentals. This should drive a greater appreciation for the company’s growth prospects and earnings potential, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $107.”
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -3.6% and a 42.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Aclaris Therapeutics Inc, and Paratek Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Perrigo Company plc with a $89.17 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $95.93 and a one-year low of $63.68. Currently, Perrigo Company plc has an average volume of 1.21M.
Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRGO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals.
